Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Amendment to the Exclusive Research, Development Option and License Agreement...Exclusive Research, Development Option and License Agreement • November 13th, 2019 • Magenta Therapeutics, Inc. • Pharmaceutical preparations
WHEREAS, the Parties have agreed to extend the term for the supply of Amanitin Toxin Construct pursuant to Section 6.1.1 (a) of the Agreement, by letter agreement dated February 28, 2019,
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT #1 TO PROJECT RIDER #3 COLLABORATION AGREEMENTCollaboration Agreement • November 13th, 2019 • Magenta Therapeutics, Inc. • Pharmaceutical preparations
This Amendment #1 (“Amendment #1”) is entered into effective as of the date of the final signature executing this Amendment #1 (“Amendment #1 Effective Date”), by and between Magenta Therapeutics, Inc. (“Magenta”) and National Marrow Donor Program d/b/a Be The Match Biotherapies (“BTMB”), (each a “Party” and collectively the “Parties”) as those Parties are defined in Attachment A, Project Rider #3, effective September 6, 2018 (collectively, the “Project Rider #3”).
